[go: up one dir, main page]

CR8519A - Nuevos pirrolocarbazoles fusionados - Google Patents

Nuevos pirrolocarbazoles fusionados

Info

Publication number
CR8519A
CR8519A CR8519A CR8519A CR8519A CR 8519 A CR8519 A CR 8519A CR 8519 A CR8519 A CR 8519A CR 8519 A CR8519 A CR 8519A CR 8519 A CR8519 A CR 8519A
Authority
CR
Costa Rica
Prior art keywords
pirrolocarbazols
fusionated
new
present
pyrrolocarbazoles
Prior art date
Application number
CR8519A
Other languages
English (en)
Inventor
C Becknell Nadine
L Diebold James
E Gingrich Diane
L Hudkins Robert
R Reddy Dandu
Tao Ming
L Underiner Theodore
L Zulli Allison
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of CR8519A publication Critical patent/CR8519A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)

Abstract

La presente invencion tiene relacion generalmente con pirrolocarbazoles fusionados, incluyendo composiciones farmaceuticas de estos y metodos para tratar enfermedades con estos. La presente invencion tambien esta dirigida a los intermediarios y procesos para elaborar estos pirrolocarbazoles.
CR8519A 2003-12-23 2006-07-19 Nuevos pirrolocarbazoles fusionados CR8519A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53218203P 2003-12-23 2003-12-23
US11/017,947 US7169802B2 (en) 2003-12-23 2004-12-22 Fused pyrrolocarbazoles

Publications (1)

Publication Number Publication Date
CR8519A true CR8519A (es) 2007-06-06

Family

ID=34703676

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8519A CR8519A (es) 2003-12-23 2006-07-19 Nuevos pirrolocarbazoles fusionados

Country Status (29)

Country Link
US (4) US7169802B2 (es)
EP (1) EP1704148B1 (es)
JP (1) JP5006046B2 (es)
KR (2) KR101179372B1 (es)
CN (1) CN1918162B (es)
AR (1) AR047168A1 (es)
AT (1) ATE500256T1 (es)
AU (1) AU2004309394B2 (es)
BR (1) BRPI0418113B8 (es)
CA (1) CA2549627C (es)
CR (1) CR8519A (es)
CY (1) CY1111524T1 (es)
DE (1) DE602004031672D1 (es)
DK (1) DK1704148T3 (es)
EA (1) EA012295B1 (es)
HR (1) HRP20110373T1 (es)
IL (1) IL176384A (es)
IS (1) IS8519A (es)
MA (1) MA28298A1 (es)
MY (2) MY143373A (es)
NO (2) NO336893B1 (es)
NZ (1) NZ548099A (es)
PL (1) PL1704148T3 (es)
PT (1) PT1704148E (es)
RS (1) RS51886B (es)
SG (1) SG149045A1 (es)
SI (1) SI1704148T1 (es)
TW (1) TWI355385B (es)
WO (1) WO2005063763A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20090270511A1 (en) * 2006-09-08 2009-10-29 Merck Frosst Canada Ltd. Prodrugs of inhibitors of cathepsin s
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
EP2167075A4 (en) * 2007-06-08 2012-07-11 Univ Massachusetts MIXED LINEAGE KINASES AND METABOLISM DISORDER
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
CA2741089A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
AU2009316600B2 (en) * 2008-11-19 2015-09-24 Cephalon, Inc. Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
EP2192121A1 (en) 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
WO2010078427A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
RU2012120783A (ru) * 2009-10-22 2013-11-27 Женентек, Инк. Модуляция дегенерации аксона
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
MY156830A (en) 2010-05-18 2016-03-31 Cephalon Inc Method for purifying a fused pyrrolocarbazole derivative
CN103664797A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
US10386370B2 (en) 2013-02-11 2019-08-20 Incuron, Inc. Use of facilitates chromatin transcription complex (FACT) in cancer
US9884853B2 (en) * 2013-09-26 2018-02-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3129022A4 (en) 2014-04-06 2018-02-21 Incuron, Llc Combination therapies with curaxins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
AU710669B2 (en) 1996-08-22 1999-09-23 Bristol-Myers Squibb Company Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US6630500B2 (en) * 2000-08-25 2003-10-07 Cephalon, Inc. Selected fused pyrrolocarbazoles
AU2001292579A1 (en) 2000-09-29 2002-04-15 Eli Lilly And Company Methods and compounds for treating proliferative diseases
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles

Also Published As

Publication number Publication date
IL176384A0 (en) 2006-10-05
HK1096096A1 (en) 2007-05-25
MY143373A (en) 2011-04-29
US20100152196A1 (en) 2010-06-17
WO2005063763A1 (en) 2005-07-14
AU2004309394A1 (en) 2005-07-14
NO20151245A1 (no) 2015-09-23
CA2549627A1 (en) 2005-07-14
KR20120066057A (ko) 2012-06-21
MA28298A1 (fr) 2006-11-01
JP2007516293A (ja) 2007-06-21
DK1704148T3 (da) 2011-06-14
US20120004253A1 (en) 2012-01-05
SI1704148T1 (sl) 2011-06-30
KR101179372B1 (ko) 2012-09-03
PL1704148T3 (pl) 2011-07-29
RS51886B (sr) 2012-02-29
CA2549627C (en) 2012-12-11
JP5006046B2 (ja) 2012-08-22
PT1704148E (pt) 2011-05-25
IS8519A (is) 2006-06-22
CN1918162B (zh) 2014-05-14
EA200601217A1 (ru) 2006-12-29
CN1918162A (zh) 2007-02-21
US7671064B2 (en) 2010-03-02
DE602004031672D1 (de) 2011-04-14
TWI355385B (en) 2012-01-01
US7169802B2 (en) 2007-01-30
EP1704148B1 (en) 2011-03-02
MY158159A (en) 2016-09-15
BRPI0418113B1 (pt) 2020-04-14
SG149045A1 (en) 2009-01-29
BRPI0418113A (pt) 2007-04-17
ATE500256T1 (de) 2011-03-15
BRPI0418113B8 (pt) 2021-05-25
EP1704148A1 (en) 2006-09-27
US8044064B2 (en) 2011-10-25
US8383813B2 (en) 2013-02-26
IL176384A (en) 2015-05-31
US20060247294A1 (en) 2006-11-02
AR047168A1 (es) 2006-01-11
NO20063196L (no) 2006-09-20
HRP20110373T1 (hr) 2011-06-30
NZ548099A (en) 2010-05-28
AU2004309394B2 (en) 2011-04-28
EA012295B1 (ru) 2009-08-28
US20050143442A1 (en) 2005-06-30
TW200530243A (en) 2005-09-16
KR20060127069A (ko) 2006-12-11
CY1111524T1 (el) 2015-08-05
NO336893B1 (no) 2015-11-23

Similar Documents

Publication Publication Date Title
CR8519A (es) Nuevos pirrolocarbazoles fusionados
HN1999000124A (es) Derivados de pirazol substituido.
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
NI200300008A (es) 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONAS.
ECSP034830A (es) Derivados sustituidos de la ciclohexano-1,4- diamina
HN2006019068A (es) "sintesis de (r)-n-metilnaltrexona"
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
GT200200228A (es) Anticuerpos para cd40
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
ECSP077321A (es) Procesos e intermediarios para preparar inhibidores de cisteína proteasa
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
SV2004001481A (es) Derivados de nicotinamida utiles como inhibidores de pde4" ref. pc22065a
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
ECSP034917A (es) Nuevos derivados de acido sulfonico
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
UY26265A1 (es) Compuestos calciolíticos
GT200500139A (es) Metodo para la preparacion de acidos hidroxamicos
DE60138371D1 (de) PROSTAGLANDINE zur Behandlung von Lichtstrahlung erzeugten Augenerkrankungen wie Photoretinitis
PA8624401A1 (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo
HN2000000056A (es) Nuevas formas cristalinas de un antibiotico macrolido